- Home
- DNLI vs CAAP Comparison
DNLI vs CAAP Comparison
Compare DNLI & CAAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- CAAP
- Stock Information
- Founded
- DNLI 2013
- CAAP 1998
- Country
- DNLI United States
- CAAP Luxembourg
- Employees
- DNLI N/A
- CAAP N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- CAAP Aerospace
- Sector
- DNLI Health Care
- CAAP Consumer Discretionary
- Exchange
- DNLI Nasdaq
- CAAP Nasdaq
- Market Cap
- DNLI 3.3B
- CAAP 3.0B
- IPO Year
- DNLI 2017
- CAAP 2018
- Fundamental
- Price
- DNLI $21.93
- CAAP $18.34
- Analyst Decision
- DNLI Strong Buy
- CAAP Strong Buy
- Analyst Count
- DNLI 13
- CAAP 1
- Target Price
- DNLI $38.91
- CAAP $21.50
- AVG Volume (30 Days)
- DNLI 1.1M
- CAAP 140.4K
- Earning Date
- DNLI 02-25-2025
- CAAP 11-20-2024
- Dividend Yield
- DNLI N/A
- CAAP N/A
- EPS Growth
- DNLI N/A
- CAAP 115.99
- EPS
- DNLI N/A
- CAAP 2.09
- Revenue
- DNLI N/A
- CAAP $1,496,122,000.00
- Revenue This Year
- DNLI N/A
- CAAP $19.21
- Revenue Next Year
- DNLI $651.24
- CAAP $14.26
- P/E Ratio
- DNLI N/A
- CAAP $8.78
- Revenue Growth
- DNLI 204.74
- CAAP N/A
- 52 Week Low
- DNLI $14.56
- CAAP $13.74
- 52 Week High
- DNLI $33.33
- CAAP $20.79
- Technical
- Relative Strength Index (RSI)
- DNLI 51.28
- CAAP 41.80
- Support Level
- DNLI $18.52
- CAAP $18.19
- Resistance Level
- DNLI $22.37
- CAAP $19.46
- Average True Range (ATR)
- DNLI 1.31
- CAAP 0.61
- MACD
- DNLI 0.31
- CAAP -0.08
- Stochastic Oscillator
- DNLI 88.57
- CAAP 7.75
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.